Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2018

View Archived Issues

RNAi-mediated beta-catenin inhibition increases response rates to cancer immunotherapy in mice

Noncoding DNA affects heart risk via noncoding RNA

Considering neighborhood improves neoantigen prediction

Loxo Oncology initiates phase I/II trial of LOXO-305 in CLL/SLL and NHL

Gritstone Oncology begins phase I/II study of personalized neoantigen cancer vaccine in solid tumors

Aravive initiates phase I/II study of AVB-S6-500 in platinum-resistant recurrent ovarian cancer

Novel 7-gene expression signature accurately predicts breast cancer outcome

Enrollment opens in two studies of Xhance

Interim phase II results presented for BP-1001 in AML

High synaptojanin 2 expression predicts poor prognosis in ER-positive breast cancer

Long noncoding RNA LINC02273 regulates oncogenic gene expression and breast cancer metastasis

ME1 is a prognostic marker and potential therapeutic target in breast cancer

High periostin levels predict shorter survival in primary, nonmetastatic breast cancer

Liver injury regeneration strategy bypasses fibrosis

Alligator Bioscience initiates first-in-human study of ATOR-1015

Aplidin approved in Australia for the treatment of multiple myeloma

Positive second cohort data from phase I study of Oraxol plus ramucirumab in gastric cancer

MyoKardia reports phase Ib data for MYK-491

Lilly identifies new calcitonin gene-related peptide receptor antagonists

New adrenomedullin-2 antagonists synthesized at the University of Sheffield

Novan reports fourth cohort data from phase II trial of SB-206 for molluscum contagiosum

FDA approves Tolsura for systemic fungal infections

Noxopharm advances DARRT-1 study of Veyonda in late-stage prostate cancer

Arcus Biosciences patents adenosine receptor A2A and/or A2B antagonists

RIP-1 inhibitors discovered at Denali Therapeutics

University of Michigan divulges lysine-specific histone demethylase 1A inhibitors

Vect-Horus enters research collaboration agreement with Janssen

Aeglea announces phase III plans for pegzilarginase in arginase 1 deficiency

FDA accepts IND for Sermonix's phase II trial of oral lasofoxifene in breast cancer